Uso bem-sucedido de rivaroxabana com níveis terapêuticos de antifator xa em paciente com obesidade mórbida e embolia pulmonar aguda de risco intermediário …
Direct oral anticoagulants (DOACs) have become the standard of care for acute and long-
term therapy for venous thromboembolism (VTE) due to their efficacy and safety profiles. The …
term therapy for venous thromboembolism (VTE) due to their efficacy and safety profiles. The …
[HTML][HTML] Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism
Direct oral anticoagulants (DOACs) have become the standard of care for acute and long-
term therapy for venous thromboembolism (VTE) due to their efficacy and safety profiles. The …
term therapy for venous thromboembolism (VTE) due to their efficacy and safety profiles. The …
Achieving Therapeutic Anti-Xa Levels Using Rivaroxaban for Venous Thromboembolism in a Morbidly Obese Patient with a BMI> 70
Background: Anticoagulation (AC) is the cornerstone of treatment for venous
thromboembolism (VTE). Direct oral anticoagulants (DOACs) have become the standard of …
thromboembolism (VTE). Direct oral anticoagulants (DOACs) have become the standard of …
Comparative effectiveness, safety, and costs of rivaroxaban and warfarin treatment among morbidly obese patients with venous thromboembolism
AC Spyropoulos, V Ashton, YW Chen, B Wu… - Blood, 2018 - ashpublications.org
Background: Use of direct-acting oral anticoagulants (DOACs) in morbidly obese (BMI> 40
kg/m 2) patients for venous thromboembolism (VTE) treatment is not fully understood …
kg/m 2) patients for venous thromboembolism (VTE) treatment is not fully understood …
Real life results of direct-acting oral anticoagulants recommended-dose in obese vs normal-weight patients with venous thromboembolism
JA Rueda-Camino, R Barba, S Otálora… - Thrombosis …, 2024 - Elsevier
Background There is scarce evidence on the effectiveness and safety of recommended-
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …
Efficacy and safety of direct oral anticoagulants in obese patients with venous thromboembolism
RA Sa, F Al-Ani, A Lazo-Langner, ML Louzada - Blood, 2019 - Elsevier
Background: Obesity is a well-known risk factor for venous thromboembolism (VTE),
however, obese patients are under-represented in clinical trials (1; 2). Four direct oral …
however, obese patients are under-represented in clinical trials (1; 2). Four direct oral …
[HTML][HTML] Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: comparative effectiveness, safety, and costs
AC Spyropoulos, V Ashton, YW Chen, B Wu… - Thrombosis research, 2019 - Elsevier
Introduction Limited data exist on direct-acting oral anticoagulants in morbidly obese
patients with venous thromboembolism (VTE). We compared clinical and health/economic …
patients with venous thromboembolism (VTE). We compared clinical and health/economic …
[引用][C] Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience
DRJ Arachchillage, R Reynolds… - Thrombosis …, 2016 - thrombosisresearch.com
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality worldwide.
Appropriate anticoagulation is crucial in the treatment and prevention of recurrent VTE …
Appropriate anticoagulation is crucial in the treatment and prevention of recurrent VTE …
Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: drug levels and clinical outcomes
A Ballerie, RN Van, K Lacut, H Galinat, C Rousseau… - Thrombosis research, 2021 - Elsevier
Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …
[HTML][HTML] Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data
OS Costa, J Beyer-Westendorf, V Ashton… - Journal of Thrombosis …, 2021 - Springer
There is limited data evaluating clinical outcomes of rivaroxaban versus warfarin in obese
patients with venous thromboembolism (VTE). Our objective was to evaluate the …
patients with venous thromboembolism (VTE). Our objective was to evaluate the …